AR127555A1 - Composiciones y métodos que comprenden dsg2 asociados a enfermedades cardíacas - Google Patents
Composiciones y métodos que comprenden dsg2 asociados a enfermedades cardíacasInfo
- Publication number
- AR127555A1 AR127555A1 ARP220103004A ARP220103004A AR127555A1 AR 127555 A1 AR127555 A1 AR 127555A1 AR P220103004 A ARP220103004 A AR P220103004A AR P220103004 A ARP220103004 A AR P220103004A AR 127555 A1 AR127555 A1 AR 127555A1
- Authority
- AR
- Argentina
- Prior art keywords
- dsg2
- protein
- arrhythmia
- treating
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 101000924314 Homo sapiens Desmoglein-2 Proteins 0.000 title abstract 2
- 102100034578 Desmoglein-2 Human genes 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 108010045583 Desmoglein 2 Proteins 0.000 abstract 10
- 102000005707 Desmoglein 2 Human genes 0.000 abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 208000002173 dizziness Diseases 0.000 abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 206010003119 arrhythmia Diseases 0.000 abstract 3
- 230000006793 arrhythmia Effects 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 206010033557 Palpitations Diseases 0.000 abstract 2
- 208000013433 lightheadedness Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010042772 syncope Diseases 0.000 abstract 2
- 241000282465 Canis Species 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000252212 Danio rerio Species 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 241000282560 Macaca mulatta Species 0.000 abstract 1
- 101100171224 Mus musculus Dsg2 gene Proteins 0.000 abstract 1
- 208000009525 Myocarditis Diseases 0.000 abstract 1
- 241000700157 Rattus norvegicus Species 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La divulgación generalmente se refiere a composiciones y métodos para tratar una enfermedad mediante la administración de las composiciones descritas en el presente documento. En el presente documento, se proporcionan polipéptidos de fusión de DSG2 y métodos relacionados que incluyen métodos de tratamiento y mejora de la función de los cardiomiocitos. Reivindicación 1: Un polipéptido aislado caracterizado porque comprende un polipéptido de fusión de desmogleína-2 (DSG2), donde el polipéptido de fusión DSG2 comprende: a. la totalidad o una porción de una proteína DSG2, donde la proteína DSG2 es una proteína DSG2 de Homo sapiens, una proteína DSG2 de Mus musculus, una proteína DSG2 de Rattus norvegicus, una proteína DSG2 de Macaca mulatta, una proteína DSG2 de Canis lupus familiaris o una proteína DSG2 de Danio rerio; y b. la totalidad o una porción de una proteína de inmunoglobulina, donde la proteína de inmunoglobulina es una proteína de inmunoglobulina humana o canina. Reivindicación 36: Un método para tratar la arritmia y/o cardiomiopatía en un sujeto, caracterizado porque comprende: poner en contacto al sujeto con el polipéptido aislado de una cualquiera de las reivindicaciones 1 a 29, o una célula de la reivindicación 30; y medir uno o más síntomas asociados con la arritmia seleccionados del grupo que consiste en palpitaciones, mareos, aturdimiento, síncope, insuficiencia cardíaca y fracción de eyección reducida; y/o medir uno o más síntomas asociados con cardiomiopatía seleccionados del grupo que consiste en arritmia, palpitaciones, aturdimiento, mareos, síncope, miocarditis, insuficiencia cardíaca, gasto cardíaco deficiente y fracción de eyección reducida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274707P | 2021-11-02 | 2021-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127555A1 true AR127555A1 (es) | 2024-02-07 |
Family
ID=84569745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103004A AR127555A1 (es) | 2021-11-02 | 2022-11-02 | Composiciones y métodos que comprenden dsg2 asociados a enfermedades cardíacas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240279304A1 (es) |
| EP (1) | EP4426430A1 (es) |
| JP (1) | JP2024540220A (es) |
| KR (1) | KR20240110819A (es) |
| CN (1) | CN118369351A (es) |
| AR (1) | AR127555A1 (es) |
| AU (1) | AU2022382972A1 (es) |
| CA (1) | CA3236070A1 (es) |
| IL (1) | IL312219A (es) |
| MX (1) | MX2024005327A (es) |
| TW (1) | TW202334190A (es) |
| WO (1) | WO2023081674A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965197A (en) | 1987-06-12 | 1990-10-23 | Massachusetts Institute Of Technology | Coryneform expression and secretion system |
| KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| DE10057397A1 (de) | 2000-11-18 | 2002-05-23 | Hella Kg Hueck & Co | Vorrichtung zur Ölstandsmessung |
| DK2147104T3 (en) | 2007-05-21 | 2015-12-14 | Danisco Us Inc | USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION |
| US8324578B2 (en) | 2008-09-30 | 2012-12-04 | Apple Inc. | Hidden sensors in an electronic device |
| US8975041B2 (en) | 2009-09-10 | 2015-03-10 | Biocon Limited | Fusion proteins and method of expression thereof |
| JP2012107935A (ja) * | 2010-11-16 | 2012-06-07 | Mitsubishi Chemicals Corp | Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法 |
| BR112013028887B1 (pt) | 2011-05-11 | 2020-10-06 | Children's Medical Center Corporation | Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos |
| WO2018129625A1 (en) * | 2017-01-13 | 2018-07-19 | The Hospital For Sick Children | Method for diagnosis of arrhythmogenic right ventricular cardiomyopathy |
| MX2023006704A (es) * | 2020-12-15 | 2023-06-20 | Arvada Therapeutics Inc | Composiciones dsg2 y metodos para el tratamiento de covid-19. |
-
2022
- 2022-11-02 AR ARP220103004A patent/AR127555A1/es unknown
- 2022-11-02 MX MX2024005327A patent/MX2024005327A/es unknown
- 2022-11-02 JP JP2024525855A patent/JP2024540220A/ja active Pending
- 2022-11-02 WO PCT/US2022/079106 patent/WO2023081674A1/en not_active Ceased
- 2022-11-02 AU AU2022382972A patent/AU2022382972A1/en active Pending
- 2022-11-02 TW TW111141818A patent/TW202334190A/zh unknown
- 2022-11-02 KR KR1020247018502A patent/KR20240110819A/ko active Pending
- 2022-11-02 IL IL312219A patent/IL312219A/en unknown
- 2022-11-02 CN CN202280073102.9A patent/CN118369351A/zh active Pending
- 2022-11-02 EP EP22829631.5A patent/EP4426430A1/en active Pending
- 2022-11-02 CA CA3236070A patent/CA3236070A1/en active Pending
-
2024
- 2024-05-01 US US18/652,115 patent/US20240279304A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4426430A1 (en) | 2024-09-11 |
| JP2024540220A (ja) | 2024-10-31 |
| WO2023081674A1 (en) | 2023-05-11 |
| MX2024005327A (es) | 2024-05-21 |
| IL312219A (en) | 2024-06-01 |
| CA3236070A1 (en) | 2023-05-11 |
| KR20240110819A (ko) | 2024-07-16 |
| AU2022382972A1 (en) | 2024-05-09 |
| TW202334190A (zh) | 2023-09-01 |
| CN118369351A (zh) | 2024-07-19 |
| US20240279304A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ohba et al. | Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men | |
| Vanderheyden et al. | Brain and other natriuretic peptides: molecular aspects | |
| Seiler et al. | Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4 | |
| Del Ry et al. | Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure | |
| Semenov et al. | Analytical issues with natriuretic peptides–has this been overly simplified? | |
| Dani et al. | Mapping the expression of soluble olfactory proteins in the honeybee | |
| Semenov et al. | Standardization of BNP and NT-proBNP immunoassays in light of the diverse and complex nature of circulating BNP-related peptides | |
| Wang et al. | The Xin repeat-containing protein, mXinβ, initiates the maturation of the intercalated discs during postnatal heart development | |
| AR127555A1 (es) | Composiciones y métodos que comprenden dsg2 asociados a enfermedades cardíacas | |
| Srivastava et al. | Levels of crystallin fragments and identification of their origin in water soluble high molecular weight (HMW) proteins of human lenses | |
| Kongsuwan et al. | Activation of several key components of the epidermal differentiation pathway in cattle following infestation with the cattle tick, Rhipicephalus (Boophilus) microplus | |
| Nagai‐Okatani et al. | Three molecular forms of atrial natriuretic peptides: quantitative analysis and biological characterization | |
| CL2023001436A1 (es) | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso | |
| Sotillo et al. | Excretory/secretory proteome of the adult stage of Echinostoma caproni | |
| Papakonstantinou et al. | Atrial fibrillation versus. atrial myopathy in thrombogenesis: Two sides of the same coin? | |
| Semenov et al. | Human pro–B-type natriuretic peptide is processed in the circulation in a rat model | |
| Essop et al. | Proteomic analysis of mitochondrial proteins in a mouse model of type 2 diabetes: cardiovascular topics | |
| Tokudome et al. | Importance of endogenous atrial and brain natriuretic peptides in murine embryonic vascular and organ development | |
| Srivastava et al. | Crosslinking of human lens 9 kDa gammaD-crystallin fragment in vitro and in vivo | |
| Dietrich et al. | Isolation, characterisation and cDNA sequencing of a new form of parvalbumin from carp semen | |
| Bhandari et al. | The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension | |
| Steri et al. | Modelling extended lactation curves for milk production traits in Italian Holsteins | |
| Abd ElHafeez et al. | Norepinephrine, left ventricular disorders and volume excess in ESRD | |
| Moreira et al. | Comparison of peak oxygen consumption and percent of predicted oxygen consumption for predicting prognosis in young and female heart failure patients | |
| Grewal et al. | The heart as an endocrine system |